First Time Loading...

Royalty Pharma PLC
NASDAQ:RPRX

Watchlist Manager
Royalty Pharma PLC Logo
Royalty Pharma PLC
NASDAQ:RPRX
Watchlist
Price: 27.675 USD -0.52% Market Closed
Updated: Apr 23, 2024

Intrinsic Value

Royalty Pharma Plc provides drug development services. [ Read More ]

The intrinsic value of one RPRX stock under the Base Case scenario is 49.064 USD. Compared to the current market price of 27.675 USD, Royalty Pharma PLC is Undervalued by 44%.

Key Points:
RPRX Intrinsic Value
Base Case
49.064 USD
Undervaluation 44%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Royalty Pharma PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling RPRX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Royalty Pharma PLC

Provide an overview of the primary business activities
of Royalty Pharma PLC.

What unique competitive advantages
does Royalty Pharma PLC hold over its rivals?

What risks and challenges
does Royalty Pharma PLC face in the near future?

Has there been any significant insider trading activity
in Royalty Pharma PLC recently?

Summarize the latest earnings call
of Royalty Pharma PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Royalty Pharma PLC.

Provide P/S
for Royalty Pharma PLC.

Provide P/E
for Royalty Pharma PLC.

Provide P/OCF
for Royalty Pharma PLC.

Provide P/FCFE
for Royalty Pharma PLC.

Provide P/B
for Royalty Pharma PLC.

Provide EV/S
for Royalty Pharma PLC.

Provide EV/GP
for Royalty Pharma PLC.

Provide EV/EBITDA
for Royalty Pharma PLC.

Provide EV/EBIT
for Royalty Pharma PLC.

Provide EV/OCF
for Royalty Pharma PLC.

Provide EV/FCFF
for Royalty Pharma PLC.

Provide EV/IC
for Royalty Pharma PLC.

Show me price targets
for Royalty Pharma PLC made by professional analysts.

What are the Revenue projections
for Royalty Pharma PLC?

How accurate were the past Revenue estimates
for Royalty Pharma PLC?

What are the Net Income projections
for Royalty Pharma PLC?

How accurate were the past Net Income estimates
for Royalty Pharma PLC?

What are the EPS projections
for Royalty Pharma PLC?

How accurate were the past EPS estimates
for Royalty Pharma PLC?

What are the EBIT projections
for Royalty Pharma PLC?

How accurate were the past EBIT estimates
for Royalty Pharma PLC?

Compare the revenue forecasts
for Royalty Pharma PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Royalty Pharma PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Royalty Pharma PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Royalty Pharma PLC compared to its peers.

Compare the P/E ratios
of Royalty Pharma PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Royalty Pharma PLC with its peers.

Analyze the financial leverage
of Royalty Pharma PLC compared to its main competitors.

Show all profitability ratios
for Royalty Pharma PLC.

Provide ROE
for Royalty Pharma PLC.

Provide ROA
for Royalty Pharma PLC.

Provide ROIC
for Royalty Pharma PLC.

Provide ROCE
for Royalty Pharma PLC.

Provide Gross Margin
for Royalty Pharma PLC.

Provide Operating Margin
for Royalty Pharma PLC.

Provide Net Margin
for Royalty Pharma PLC.

Provide FCF Margin
for Royalty Pharma PLC.

Show all solvency ratios
for Royalty Pharma PLC.

Provide D/E Ratio
for Royalty Pharma PLC.

Provide D/A Ratio
for Royalty Pharma PLC.

Provide Interest Coverage Ratio
for Royalty Pharma PLC.

Provide Altman Z-Score Ratio
for Royalty Pharma PLC.

Provide Quick Ratio
for Royalty Pharma PLC.

Provide Current Ratio
for Royalty Pharma PLC.

Provide Cash Ratio
for Royalty Pharma PLC.

What is the historical Revenue growth
over the last 5 years for Royalty Pharma PLC?

What is the historical Net Income growth
over the last 5 years for Royalty Pharma PLC?

What is the current Free Cash Flow
of Royalty Pharma PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Royalty Pharma PLC.

Financials

Balance Sheet Decomposition
Royalty Pharma PLC

Current Assets 1.3B
Cash & Short-Term Investments 1.2B
Receivables 36.6m
Other Current Assets 3.8m
Non-Current Assets 15.1B
Long-Term Investments 15.1B
Other Non-Current Assets 6.5m
Current Liabilities 161.4m
Accounts Payable 15.2m
Accrued Liabilities 51.7m
Other Current Liabilities 94.5m
Non-Current Liabilities 9.7B
Long-Term Debt 6.1B
Other Non-Current Liabilities 3.6B
Efficiency

Earnings Waterfall
Royalty Pharma PLC

Revenue
2.4B USD
Operating Expenses
-862.4m USD
Operating Income
1.5B USD
Other Expenses
-357.3m USD
Net Income
1.1B USD

Free Cash Flow Analysis
Royalty Pharma PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

RPRX Profitability Score
Profitability Due Diligence

Royalty Pharma PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

Positive Operating Income
Positive Free Cash Flow
Positive Net Income
Positive Revenue Growth Forecast
57/100
Profitability
Score

Royalty Pharma PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

RPRX Solvency Score
Solvency Due Diligence

Royalty Pharma PLC's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
40/100
Solvency
Score

Royalty Pharma PLC's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RPRX Price Targets Summary
Royalty Pharma PLC

Wall Street analysts forecast RPRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RPRX is 46.41 USD with a low forecast of 37.37 USD and a high forecast of 63 USD.

Lowest
Price Target
37.37 USD
35% Upside
Average
Price Target
46.41 USD
68% Upside
Highest
Price Target
63 USD
128% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

RPRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

RPRX Price
Royalty Pharma PLC

1M 1M
-9%
6M 6M
+1%
1Y 1Y
-22%
3Y 3Y
-34%
5Y 5Y
-34%
10Y 10Y
-34%
Annual Price Range
27.675
52w Low
26.21
52w High
35.61
Price Metrics
Average Annual Return -2.2%
Standard Deviation of Annual Returns 11.01%
Max Drawdown -48%
Shares Statistics
Market Capitalization 16.5B USD
Shares Outstanding 597 430 000
Percentage of Shares Shorted 2.89%

RPRX Return Decomposition
Main factors of price return

What is price return decomposition?

RPRX News

Other Videos

Last Important Events
Royalty Pharma PLC

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Royalty Pharma PLC

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Royalty Pharma PLC Logo
Royalty Pharma PLC

Country

United States of America

Industry

Pharmaceuticals

Market Cap

16.5B USD

Dividend Yield

3.04%

Description

Royalty Pharma Plc provides drug development services. The company is headquartered in New York City, New York and currently employs 66 full-time employees. The company went IPO on 2020-06-16. The firm invests in academic institutions, research hospitals and not-for-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investments includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta, OXLUMO and five development-stage product candidates.

Contact

NEW YORK
New York City
110 East 59Th Street
+12128830200.0
https://www.royaltypharma.com

IPO

2020-06-16

Employees

66

Officers

Founder, Chairman of the Board & CEO
Mr. Pablo Gerardo Legorreta
Executive VP & CFO
Mr. Terrance P. Coyne
Executive VP of Investments & Chief Legal Officer
Mr. George Wingate Lloyd
Vice Chairman & Executive VP
Mr. Christopher Hite
Executive VP and Head of Research & Investments
Dr. Marshall Urist M.D., Ph.D.
Executive Vice President of Investments & General Counsel
Mr. Arthur R. McGivern J.D.
Show More
Executive Vice President of Investments
Mr. Ashwin Pai M.D.
Senior VP & Chief Accounting Officer
Ms. Kristin Stafford
Senior VP & Chief Technology Officer
Mr. Eric Schneider
Executive VP of Investments & Chief Scientific Officer
Dr. James Folmar Reddoch Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one RPRX stock?

The intrinsic value of one RPRX stock under the Base Case scenario is 49.064 USD.

Is RPRX stock undervalued or overvalued?

Compared to the current market price of 27.675 USD, Royalty Pharma PLC is Undervalued by 44%.